findmyKOL

Saravanan Balamuthusamy, MD

Basic profile

Texas Christian University

ORCIDNPI
RegionFort Worth, TX · South CentralSpecialtyNephrologyFocusNephrology
ActivityNot yet indexedEmergingfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Saravanan Balamuthusamy is a Nephrology physician affiliated with Texas Christian University. OpenAlex indexes 64 publications with 1,212 citations (h-index 18).

Overview

Scholarship

indexed output and impact (OpenAlex)
64publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,212citations

Total citations across indexed works.

18h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
56companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

56 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

56 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    46.5%
    Calcium channel blocker12.2%
    Nifedipine Er69%Amlodipine Besylate32%
    Part D40 patients
    Beta blocker9.7%
    Carvedilol53%Metoprolol Succinate29%Labetalol Hcl9%Metoprolol Tartrate9%
    Part D<11 patients

    + 9 more classes in this area

  • Nervous system

    24%
    Benzodiazepine12.7%
    Midazolam hydrochloride82%Lorazepam12%Clonazepam6%
    Part D + Part B<11 patients
    Opioid Agonist9.5%
    Fentanyl citrate100%
    Part B, office-administered103 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    15%
    SGLT2 inhibitor3.2%
    Farxiga62%Jardiance38%
    Part D<11 patients
    Proton pump inhibitor2.4%
    Omeprazole55%Pantoprazole Sodium45%
    Part D<11 patients

    + 8 more classes in this area

Where care is delivered (Part B)10.6% facility · 89.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”